BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Gerhard GS, DiStefano JK. Micro RNAs in the development of non-alcoholic fatty liver disease. World J Hepatol 2015; 7(2): 226-234 [PMID: 25729477 DOI: 10.4254/wjh.v7.i2.226]
URL: https://www.wjgnet.com/1948-5182/full/v7/i2/226.htm
Number Citing Articles
1
Giovanni Targher, Christopher D. Byrne. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney diseaseNature Reviews Nephrology 2017; 13(5): 297 doi: 10.1038/nrneph.2017.16
2
G. Song, H. Vollbrecht. Translating MicroRNAs to the Clinic2017; : 93 doi: 10.1016/B978-0-12-800553-8.00005-6
3
Antonella Borrelli, Patrizia Bonelli, Franca Maria Tuccillo, Ira D. Goldfine, Joseph L. Evans, Franco Maria Buonaguro, Aldo Mancini. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approachesRedox Biology 2018; 15: 467 doi: 10.1016/j.redox.2018.01.009
4
Laura Belloni, Silvia Di Cocco, Francesca Guerrieri, Abigail D. G. Nunn, Silvia Piconese, Debora Salerno, Barbara Testoni, Claudio Pulito, Federica Mori, Matteo Pallocca, Andrea Sacconi, Elisa Vivoli, Fabio Marra, Sabrina Strano, Giovanni Blandino, Massimo Levrero, Natalia Pediconi. Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo modelScientific Reports 2018; 8(1) doi: 10.1038/s41598-018-31835-2
5
Erica Novo, Claudia Bocca, Beatrice Foglia, Francesca Protopapa, Marina Maggiora, Maurizio Parola, Stefania Cannito. Liver fibrogenesis: un update on established and emerging basic conceptsArchives of Biochemistry and Biophysics 2020; 689: 108445 doi: 10.1016/j.abb.2020.108445
6
Jian Zhang, Catherine A Powell, Matthew K Kay, Ravi Sonkar, Sunitha Meruvu, Mahua Choudhury. Effect of Chronic Western Diets on Non-Alcoholic Fatty Liver of Male Mice Modifying the PPAR-γ Pathway via miR-27b-5p RegulationInternational Journal of Molecular Sciences 2021; 22(4): 1822 doi: 10.3390/ijms22041822
7
Shaimaa H. Gadallah, Sanaa Eissa, Hala M. Ghanem, Emad K. Ahmed, Amany Helmy Hasanin, Manal M. El Mahdy, Marwa Matboli. Probiotic-prebiotic-synbiotic modulation of (YAP1, LATS1 and NF2 mRNAs/miR-1205/lncRNA SRD5A3-AS1) panel in NASH animal modelBiomedicine & Pharmacotherapy 2021; 140: 111781 doi: 10.1016/j.biopha.2021.111781
8
Bo Zhu, Siu-Lung Chan, Jack Li, Kathryn Li, Hao Wu, Kui Cui, Hong Chen. Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and TreatmentFrontiers in Cardiovascular Medicine 2021; 8 doi: 10.3389/fcvm.2021.742382
9
Shuangdong Chen, Yixiao Gu, Qinxue Dai, Yanshu He, Junlu Wang. Spinal miR-34a regulates inflammatory pain by targeting SIRT1 in complete Freund's adjuvant miceBiochemical and Biophysical Research Communications 2019; 516(4): 1196 doi: 10.1016/j.bbrc.2019.07.002
10
Xu Zhang, Xuetao Ji, Qian Wang, John Zhong Li. New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD)Protein & Cell 2018; 9(2): 164 doi: 10.1007/s13238-017-0436-0
11
Fan‐He Song, Dai‐Qiang Liu, Ya‐Qun Zhou, Wei Mei. SIRT1: A promising therapeutic target for chronic painCNS Neuroscience & Therapeutics 2022; 28(6): 818 doi: 10.1111/cns.13838
12
Qiaozhu Su, Virender Kumar, Neetu Sud, Ram I. Mahato. MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosisAdvanced Drug Delivery Reviews 2018; 129: 54 doi: 10.1016/j.addr.2018.01.009
13
Moustafa Nouh Elemeery. Hepatitis C - From Infection to Cure2018;  doi: 10.5772/intechopen.76209
14
Giovanni Musso, Maurizio Cassader, Solomon Cohney, Franco De Michieli, Silvia Pinach, Francesca Saba, Roberto Gambino. Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic OpportunitiesDiabetes Care 2016; 39(10): 1830 doi: 10.2337/dc15-1182
15
Cene Skubic, Živa Drakulić, Damjana Rozman. Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugsExpert Opinion on Drug Metabolism & Toxicology 2018; 14(8): 831 doi: 10.1080/17425255.2018.1492552
16
Alan Eduardo Botello-Manilla, Norberto Carlos Chávez-Tapia, Misael Uribe, Natalia Nuño-Lámbarri. Genetics and epigenetics purpose in nonalcoholic fatty liver diseaseExpert Review of Gastroenterology & Hepatology 2020; 14(8): 733 doi: 10.1080/17474124.2020.1780915
17
Siti Aishah Sulaiman, Nor I. A. Muhsin, Rahman Jamal. Regulatory Non-coding RNAs Network in Non-alcoholic Fatty Liver DiseaseFrontiers in Physiology 2019; 10 doi: 10.3389/fphys.2019.00279
18
Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Abilash Valsala Gopalakrishnan, Ramkumar Katturajan, Sandra Kannampuzha, Reshma Murali, Arunraj Namachivayam, Raja Ganesan, Kaviyarasi Renu, Abhijit Dey, Balachandar Vellingiri, Sabina Evan Prince. Exploring the Regulatory Role of ncRNA in NAFLD: A Particular Focus on PPARsCells 2022; 11(24): 3959 doi: 10.3390/cells11243959
19
Reda Albadawy, Sara H. A. Agwa, Eman Khairy, Maha Saad, Naglaa El Touchy, Mohamed Othman, Marwa Matboli. Clinical Significance of HSPD1/MMP14/ITGB1/miR-6881-5P/Lnc-SPARCL1-1:2 RNA Panel in NAFLD/NASH Diagnosis: Egyptian Pilot StudyBiomedicines 2021; 9(9): 1248 doi: 10.3390/biomedicines9091248
20
Bo Zhu, Hao Wu, Kathryn S. Li, Shahram Eisa-Beygi, Bandana Singh, Diane R. Bielenberg, Wendong Huang, Hong Chen. Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosisVascular Pharmacology 2024; 154: 107249 doi: 10.1016/j.vph.2023.107249
21
Reda Albadawy, Sara H. A. Agwa, Eman Khairy, Maha Saad, Naglaa El Touchy, Mohamed Othman, Mohamed El Kassas, Marwa Matboli. Circulatory Endothelin 1-Regulating RNAs Panel: Promising Biomarkers for Non-Invasive NAFLD/NASH Diagnosis and Stratification: Clinical and Molecular Pilot StudyGenes 2021; 12(11): 1813 doi: 10.3390/genes12111813
22
Maria Vulf, Daria Shunkina, Aleksandra Komar, Maria Bograya, Pavel Zatolokin, Elena Kirienkova, Natalia Gazatova, Ivan Kozlov, Larisa Litvinova. Analysis of miRNAs Profiles in Serum of Patients With Steatosis and SteatohepatitisFrontiers in Cell and Developmental Biology 2021; 9 doi: 10.3389/fcell.2021.736677
23
Yuping Wang, Zhichao Liu, Wen Zou, Huixiao Hong, Hong Fang, Weida Tong. Molecular Regulation of Mirnas and Potential Biomarkers in the Progression of Hepatic Steatosis to NASHBiomarkers in Medicine 2015; 9(11): 1189 doi: 10.2217/bmm.15.70
24
Li Wang, Mengyun Sun, Yue Cao, Lingyu Ma, Yang Shen, Arina Alekseevna Velikanova, Xianan Li, Changhao Sun, Yan Zhao. miR-34a regulates lipid metabolism by targeting SIRT1 in non-alcoholic fatty liver disease with iron overloadArchives of Biochemistry and Biophysics 2020; 695: 108642 doi: 10.1016/j.abb.2020.108642
25
Johanna K. DiStefano, Glenn S. Gerhard. Circulating microRNAs in nonalcoholic fatty liver diseaseExpert Review of Gastroenterology & Hepatology 2016; 10(2): 161 doi: 10.1586/17474124.2016.1125290
26
Mohamed Zaiou. Peroxisome Proliferator-Activated Receptor-γ as a Target and Regulator of Epigenetic Mechanisms in Nonalcoholic Fatty Liver DiseaseCells 2023; 12(8): 1205 doi: 10.3390/cells12081205
27
Fatemeh Kalaki-Jouybari, Mehrnoosh Shanaki, Maryam Delfan, Sattar Gorgani-Firouzjae, Soheyla Khakdan. High-intensity interval training (HIIT) alleviated NAFLD feature via miR-122 induction in liver of high-fat high-fructose diet induced diabetic ratsArchives of Physiology and Biochemistry 2020; 126(3): 242 doi: 10.1080/13813455.2018.1510968
28
Arshad Mehmood, Lei Zhao, Yong Wang, Fei Pan, Shuai Hao, Huimin Zhang, Asra Iftikhar, Muhammad Usman. Dietary anthocyanins as potential natural modulators for the prevention and treatment of non-alcoholic fatty liver disease: A comprehensive reviewFood Research International 2021; 142: 110180 doi: 10.1016/j.foodres.2021.110180
29
Victor Constantin Stoica, Dimitri Apostol, Mihai Mircea Diculescu, Iuliana Petronela Gârdan, Daniel Adrian Gârdan, Ion Mărunțelu, Ileana Constantinescu. Time for micro-RNAs in steatotic liver disease: a case–control studyFrontiers in Endocrinology 2024; 15 doi: 10.3389/fendo.2024.1349524
30
Qianying Zuo, Nicole Hwajin Park, Jenna Kathryn Lee, Ashlie Santaliz-Casiano, Zeynep Madak-Erdogan. Navigating nonalcoholic fatty liver disease (NAFLD): Exploring the roles of estrogens, pharmacological and medical interventions, and life styleSteroids 2023; : 109330 doi: 10.1016/j.steroids.2023.109330
31
W Shan, L Gao, W Zeng, Y Hu, G Wang, M Li, J Zhou, X Ma, X Tian, J Yao. Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver diseaseCell Death & Disease 2015; 6(7): e1833 doi: 10.1038/cddis.2015.196
32
Luca Valenti, Serena Pelusi. Non-Alcoholic Fatty Liver Disease2020; : 129 doi: 10.1007/978-3-319-95828-6_7
33
Somaya Albhaisi, Arun J. Sanyal. Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to DatePharmaceutical Medicine 2019; 33(6): 451 doi: 10.1007/s40290-019-00305-z
34
Soraiya Ebrahimpour-Koujan, Amir Ali Sohrabpour, Edward Giovannucci, Akram Vatannejad, Ahmad Esmaillzadeh. Effects of vitamin D supplementation on liver fibrogenic factors, vitamin D receptor and liver fibrogenic microRNAs in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: an exploratory randomized clinical trialNutrition Journal 2024; 23(1) doi: 10.1186/s12937-024-00911-x
35
Marwa Matboli, Shaimaa H. Gadallah, Wafaa M. Rashed, Amany Helmy Hasanin, Nada Essawy, Hala M. Ghanem, Sanaa Eissa. mRNA-miRNA-lncRNA Regulatory Network in Nonalcoholic Fatty Liver DiseaseInternational Journal of Molecular Sciences 2021; 22(13): 6770 doi: 10.3390/ijms22136770
36
Mohammed Eslam, Luca Valenti, Stefano Romeo. Genetics and epigenetics of NAFLD and NASH: Clinical impactJournal of Hepatology 2018; 68(2): 268 doi: 10.1016/j.jhep.2017.09.003
37
Mona A Hegazy, Ibrahim Abd ALgwad, Soheir Abuel Fadl, Mohamed Sayed Hassan, Laila Ahmed Rashed, Maha A Hussein. Serum Micro-RNA-122 Level as a Simple Noninvasive Marker of MAFLD SeverityDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2021; : 2247 doi: 10.2147/DMSO.S291595